ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

QTTB vs ABEO // OPERATING MARGIN

Q32 Bio Inc. (NASDAQ) VS. Abeona Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: QTTB 7 — ABEO 0
▲ OPERATING MARGIN LEADER: QTTB
operating-margins
31.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QTTB VS. ABEO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC QTTB ABEO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 73.70% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 QTTB /roic <GO>
EV/EBITDA & P/E Valuation 12.8x — — TIE /valuation <GO>
Free Cash Flow Yield -12.70% — — TIE /fcf-yield <GO>
Operating Margin ACTIVE 31.50% -60.00% +91.50 QTTB /operating-margins <GO>
Net Profit Margin 55.50% -60.00% +115.50 QTTB /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.99 0.20 +5.79 QTTB /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 QTTB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.1 36.1 +12.05 QTTB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 8.3x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $264.1M $260.8M $3.3M QTTB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR QTTB REV ABEO REV QTTB GROSS % ABEO GROSS % QTTB FCF ABEO FCF
FY 2025 $53.7M $5.8M — 73.7% -$33.5M -$84.3M
FY 2024 $0 $0 — — -$67.8M -$58.5M
FY 2023 $1.2M $3.5M — — -$18.7M -$37.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QTTB // BETA —
ABEO // BETA —